 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a699058 |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | Low |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H42Cl2N4O2+2 |
| Molar mass | 537.57 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Ambenonium (asambenonium dichloride, trade nameMytelase) is acholinesterase inhibitor[1] used in the management ofmyasthenia gravis.
It is classified as a reversible cholinesterase inhibitor.[2]
Ambenonium exerts its actions againstmyasthenia gravis by competitive reversible inhibition ofacetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. Myasthenia gravis occurs when the body produces antibodies against acetylcholine receptors, and thus inhibits signal transmission across the neuromuscular junction. Ambenonium reversibly binds acetylcholinesterase, inactivates it and therefore increases levels of acetylcholine. This, in turn, facilitates transmission of impulses across the myoneural junction and effectively treats the disease.
Ambenonium is used to treat muscle weakness due to disease or defect of the neuromuscular junction (myasthenia gravis).
Ambenonium was withdrawn from the market in the United States in 2010.[3]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
